LONDON (Alliance News) - BTG PLC Monday strengthened its expectations for its full year, saying it now expects its revenues to be around the top end of its guidance range of GBP330 million to GBP345 million, despite adverse foreign exchange movements, as a result of a strong first half.
The specialist healthcare group said it had continued to see good growth in the products it acquired in July 2013, TheraSphere for the treatment of liver cancer and EKOS for blood clots.
Its DC Bead treatment for the embolisation of malignant hypervascularised tumours was approved in China, and BTG is preparing for a commercial launch of the product. Additionally, it saw its first commercial sales from its treatment for varicose veins Varithena in August; the company said sales had built gradually in line with its expectations.
Its Specialty Pharmaceutical division saw a strong performance as its digoxin overdose product DigiFab and its high-dose methotrexate toxicity treatment Voraxaze continued to see growth, supported by steady sales from its antivenin CroFab.
It saw licensing revenues increase due to growth from Johnson & Johnson's prostate cancer treatment Zytiga.
"We enter the second half of the year confident of continuing this strong momentum," said Chief Executive Louise Makin in a statement.
BTG said it will release its results for the half year to end-September on November 11.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
